Summary

The global hematology analyzers and reagents market is projected to reach USD 8.8 billion by 2029 from USD 6.6 billion in 2024, growing at a CAGR of 6.1% during the forecast period. The technological advancements of hematology analyzers and reagents methods are one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of hematology analyzers and reagents, the lack of skilled professionals in emerging countries, along the slow adoption of advanced hematology instruments in emerging economies affect the growth of the hematology analyzers and reagents market.

“The hematology products and services segment to hold the largest share of the market in 2024.”
Based on product and services, hematology analyzers and reagents are segmented into hematology products and services, hemostasis products and services and immunohematology products and services. The hematology products & services segment is expected to dominate the hematology analyzers and reagents market during the forecast period. Further the hematology products & services segment is divided into three sub-segments: instruments, reagents and consumables and services. With the increasing adoption of POC testing hematology analyzers in emerging economies and the launch of technologically advanced hematology products worldwide leads to the growth of this market segment.

“The low-range hematology analyzers segment to hold the largest share of the market in 2024.”
Based on price range, the hematology analyzers and reagents market is segmented into high-range hematology analyzers, mid-range hematology analyzers and low-range hematology analyzers. The hematology analyzers and reagents market is expected to be dominated by the low-range hematology analyzers segment during the forecast period. The low-range hematology analyzers are expected to grow due to their affordable costing compared to high-range hematology analyzers and mid-range hematology analyzers

“The standalone analyzers segment to hold the largest share of the market in 2024.”
Based on the usage type, the hematology analyzers and reagents market is segmented into standalone analyzers and point-of-care analyzers segments. The standalone analyzers segment is projected to dominate the hematology analyzers and reagents market throughout the forecast period. Growing adoption of these systems in acute care settings for hospitals and reference laboratories. leads to the increasing growth of the segment in the market.
“The commercial service providers segment to hold the largest share of the market in 2024.”
The end user market is segmented into commercial service providers, hospital laboratories, government reference laboratories, and research & academic institutes. Commercial service providers accounted for the largest share of the global hematology analyzers and reagents market in 2023 during the forecasted years. This can be attributed to the attributed to the growing outsourcing of R&D activities to commercial service providers especially in emerging economies.

“The market in the APAC region is expected to register highest growth rate for hematology analyzers and reagents in 2024.”
The hematology analyzers and reagents market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for hematology analyzers and reagents was held by the market in the North American region, comprising the US and Canada. On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. The increasing market penetration opportunities in emerging APAC countries led to the growth of the hematology analyzers and reagents market in this region.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1– 25%, Tier 2– 30%, and Tier 3– 45%
• By Designation: D-level– 30%, C- Level– 23%, and Others– 47%
• By Region: North America– 40%, Europe– 30%, Asia Pacific– 22%, Latin America- 6%, MEA- 2%

The prominent players in the hematology analyzers and reagents market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Diatron (Hungary), Drew Scientific (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Horiba Ltd. (Japan), Nihon Kohden Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BioSystems (Spain), and QuidelOrtho Corporation (US), among others.

Research Coverage
This report studies the hematology analyzers and reagents market based on product and services, price range, application, modality, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:
• Analysis of key drivers (Increasing need for technological advancements, Integration of hematology analyzers with flow cytometry, Increasing number of blood donations), restraints (High costs associated with advanced hematology analyzers), opportunities (Increased awareness among end users about advanced hematology analyzers, Increasing market penetration opportunities in emerging countries, Emergence of microfluidics), and challenges (Stringent and time-consuming regulatory process) influencing the growth of the hematology analyzers and reagents market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the hematology analyzers and reagents market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the hematology analyzers and reagents market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the hematology analyzers and reagents market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 YEARS CONSIDERED 31
1.3.3 CURRENCY CONSIDERED 31
1.4 MARKET STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 List of secondary sources 35
2.1.2 PRIMARY DATA 36
2.2 MARKET ESTIMATION METHODOLOGY 37
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 38
2.2.2 PRODUCT-BASED MARKET ESTIMATION 40
2.2.3 PRIMARY RESEARCH VALIDATION 41
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 42
2.4 RESEARCH ASSUMPTIONS 43
2.4.1 STUDY ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 44
2.6 RISK ASSESSMENT 45
2.6.1 RISK ASSESSMENT ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET OVERVIEW 51
4.2 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT AND COUNTRY (2023) 52
4.3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REGIONAL MIX,
2022–2029 (USD MILLION) 53
 
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing incidence of blood disorders 55
5.2.1.2 Growing number of blood donations 55
5.2.1.3 Rising technological advancements 56
5.2.1.4 Integration of hematology analyzers with flow cytometry 56
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of advanced hematology analyzers 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Increasing uptake of automated hematology analyzers 57
5.2.3.2 Growth potential of emerging economies 58
5.2.3.3 Emergence of microfluidics 58
5.2.4 CHALLENGES 59
5.2.4.1 Stringent regulatory guidelines 59
5.2.4.2 Shortage of skilled professionals in emerging markets 59
5.3 REGULATORY SCENARIO 60
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 60
5.3.2 REGULATORY TRENDS 62
5.3.2.1 North America 62
5.3.2.1.1 US 62
5.3.2.2 Europe 63
5.3.2.3 Asia Pacific 63
5.3.2.3.1 India 63
5.3.2.3.2 China 64
5.4 REIMBURSEMENT SCENARIO 64
5.5 VALUE CHAIN ANALYSIS 65
5.5.1 RESEARCH & DEVELOPMENT 65
5.5.2 PROCUREMENT & PRODUCT DEVELOPMENT 65
5.5.3 MARKETING, SALES, AND DISTRIBUTION 65
5.6 SUPPLY CHAIN ANALYSIS 66
5.6.1 PROMINENT COMPANIES 66
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 66
5.6.3 END USERS 66
5.7 ECOSYSTEM ANALYSIS 67
 
5.8 PORTER’S FIVE FORCES ANALYSIS 69
5.8.1 DEGREE OF COMPETITION 70
5.8.2 BARGAINING POWER OF BUYERS 71
5.8.3 BARGAINING POWER OF SUPPLIERS 71
5.8.4 THREAT OF NEW ENTRANTS 71
5.8.5 THREAT OF SUBSTITUTES 71
5.9 TRADE DATA ANALYSIS 72
5.10 PATENT ANALYSIS 73
5.11 PRICING ANALYSIS 74
5.12 TECHNOLOGY ANALYSIS 78
5.12.1 KEY TECHNOLOGIES 78
5.12.1.1 Flow cytometry 78
5.12.1.2 Digital microscopy and image analysis 78
5.12.1.3 Polymerase chain reaction (PCR) and next-generation sequencing (NGS) 78
5.12.1.4 Microfluidics 79
5.12.2 ADJACENT TECHNOLOGIES 79
5.12.2.1 Bioinformatics 79
5.12.2.2 Wearable health technology 79
5.12.2.3 Point-of-care testing (POCT) devices 79
5.12.3 COMPLEMENTARY TECHNOLOGIES 80
5.12.3.1 Immunohistochemistry (IHC) 80
5.12.3.2 Spectrophotometry 80
5.12.3.3 Serological testing 80
5.13 KEY CONFERENCES AND EVENTS, 2024 80
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 81
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
5.14.2 KEY BUYING CRITERIA 83
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 84
5.16 INVESTMENT & FUNDING SCENARIO 84
5.17 UNMET NEEDS 86
5.18 USE OF GENERATIVE AI IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 87
6 HEMATOLOGY ANALYZERS AND REAGENTS MARKET,
BY PRODUCT & SERVICE 88
6.1 INTRODUCTION 89
6.2 HEMATOLOGY PRODUCTS & SERVICES 89
6.2.1 REAGENTS & CONSUMABLES 90
6.2.1.1 Hematology reagents 92
6.2.1.1.1 Growing preference for reagent rental business models to drive market 92
 
6.2.1.2 Hematology consumables 93
6.2.1.2.1 Recurring requirement to boost demand 93
6.2.1.3 Controls & calibrators 93
6.2.1.3.1 Ability to monitor multiple parameters to fuel uptake 93
6.2.1.4 Slide stainers & makers 94
6.2.1.4.1 Ability to provide reliable & uniform staining results to fuel uptake 94
6.2.2 INSTRUMENTS 95
6.2.2.1 5-part and 6-part fully automated hematology analyzers 96
6.2.2.1.1 Identification and classification of WBCs to drive market 96
6.2.2.2 3-part fully automated hematology analyzers 97
6.2.2.2.1 Low maintenance costs to fuel uptake 97
6.2.2.3 Point-of-care testing hematology analyzers 98
6.2.2.3.1 Increasing preference towards home testing of blood levels to support market growth 98
6.2.2.4 Semi-automated hematology analyzers 99
6.2.2.4.1 Need for manual interruption to restrain market adoption 99
6.2.3 SERVICES 100
6.2.3.1 High adoption of diagnostic techniques to boost demand 100
6.3 HEMOSTASIS PRODUCTS & SERVICES 101
6.3.1 HEMOSTASIS REAGENTS & CONSUMABLES 102
6.3.1.1 Rising prevalence of coagulation disorders to support growth 102
6.3.2 HEMOSTASIS INSTRUMENTS 102
6.3.2.1 High productivity with low complexities to drive market 102
6.3.3 HEMOSTASIS SERVICES 103
6.3.3.1 Advancements in hemostasis diagnostic techniques to support market growth 103
6.4 IMMUNOHEMATOLOGY PRODUCTS & SERVICES 104
6.4.1 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES 105
6.4.1.1 Development of novel immunohematology reagents to drive market 105
6.4.2 IMMUNOHEMATOLOGY INSTRUMENTS 105
6.4.2.1 Growing automation in immunohematology labs to boost demand 105
6.4.3 SERVICES 106
6.4.3.1 Provision of customer-focused care to support market growth 106
7 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE 107
7.1 INTRODUCTION 108
7.2 LOW-RANGE HEMATOLOGY ANALYZERS 108
7.2.1 LOW OPERATING EXPENSES TO BOOST DEMAND 108
7.3 HIGH-RANGE HEMATOLOGY ANALYZERS 109
7.3.1 HIGH ACCURACY AND MULTI-PARAMETER APPROACH TO DRIVE MARKET 109
 
7.4 MID-RANGE HEMATOLOGY ANALYZERS 110
7.4.1 INTEGRATION WITH QUALITY CONTROL SOFTWARE TO SUPPORT MARKET GROWTH 110
8 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION 112
8.1 INTRODUCTION 113
8.2 HEMORRHAGIC CONDITIONS 113
8.2.1 ABILITY TO TRACK HEMOGLOBIN AND HEMATOCRIT VALUES TO DRIVE MARKET 113
8.3 INFECTIOUS DISEASES 114
8.3.1 AVAILABILITY OF HIGH-RESOLUTION HEMATOLOGY SCREENING TO PROPEL MARKET 114
8.4 IMMUNE SYSTEM DISORDERS 115
8.4.1 GROWING USE OF POC DIAGNOSTICS AND IMMUNOASSAYS TO PROPEL MARKET 115
8.5 BLOOD CANCER 116
8.5.1 DETERMINATION OF HEMATOLOGICAL MALIGNANCIES TO FUEL UPTAKE 116
8.6 ANEMIA 117
8.6.1 ABILITY TO IDENTIFY ISOCHROMATIC AND MICROCYTIC ANEMIA TO SUPPORT MARKET GROWTH 117
8.7 OTHER APPLICATIONS 118
9 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE 119
9.1 INTRODUCTION 120
9.2 STANDALONE ANALYZERS 120
9.2.1 HIGH UPTAKE IN HOSPITALS AND REFERENCE LABORATORIES FOR CRITICAL CARE SETTINGS TO PROPEL MARKET 120
9.3 POINT-OF-CARE ANALYZERS 121
9.3.1 LOW SAMPLE REQUIREMENTS AND REMOTE CARE AVAILABILITY TO BOOST DEMAND 121
10 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER 123
10.1 INTRODUCTION 124
10.2 COMMERCIAL SERVICE PROVIDERS 124
10.2.1 GROWING OUTSOURCING OF R&D ACTIVITIES AND ABILITY TO PERFORM HIGH VOLUME OF TESTS TO PROPEL MARKET 124
10.3 HOSPITAL LABORATORIES 126
10.3.1 PROVISION OF POC & FULLY AUTOMATED ANALYZERS TO DRIVE MARKET 126
10.4 GOVERNMENT REFERENCE LABORATORIES 127
10.4.1 FREE SERVICES AND RAPID TURNAROUND TIME TO FUEL UPTAKE 127
10.5 RESEARCH & ACADEMIC INSTITUTES 127
10.5.1 INCREASING NUMBER OF DRUG DISCOVERY & RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 127
 
11 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION 129
11.1 INTRODUCTION 130
11.2 NORTH AMERICA 131
11.2.1 US 136
11.2.1.1 Rising incidence of anemia and hemophilia to drive market 136
11.2.2 CANADA 139
11.2.2.1 Growth in organ transplantation procedures to boost demand 139
11.3 EUROPE 142
11.3.1 GERMANY 147
11.3.1.1 Rising prevalence of HIV to drive market 147
11.3.2 FRANCE 150
11.3.2.1 Stringent regulatory protocols in diagnostics to propel market 150
11.3.3 UK 153
11.3.3.1 Rising number of organ transplant procedures to support market growth 153
11.3.4 ITALY 156
11.3.4.1 Growing acceptance of hematology-based diagnostics to boost demand 156
11.3.5 SPAIN 159
11.3.5.1 Rising establishment of reference laboratories to drive market 159
11.3.6 REST OF EUROPE 162
11.4 ASIA PACIFIC 165
11.4.1 CHINA 171
11.4.1.1 Large target patient population to drive market 171
11.4.2 JAPAN 174
11.4.2.1 Rising cases of influenza to support market growth 174
11.4.3 INDIA 177
11.4.3.1 Rising cases of dengue and malaria to boost demand 177
11.4.4 AUSTRALIA 180
11.4.4.1 Rising prevalence of celiac disease to drive market 180
11.4.5 SOUTH KOREA 183
11.4.5.1 High healthcare expenditure and introduction of medical coverage for blood transfusion to support market growth 183
11.4.6 REST OF ASIA PACIFIC 186
11.5 LATIN AMERICA 189
11.5.1 BRAZIL 194
11.5.1.1 Investments by leading hematology analyzers & reagent manufacturers to drive market 194
11.5.2 MEXICO 197
11.5.2.1 Growing requirement for glycosylated hemoglobin analysis tests to fuel uptake 197
11.5.3 REST OF LATIN AMERICA 200
 
11.6 MIDDLE EAST & AFRICA 203
11.6.1 GCC COUNTRIES 208
11.6.1.1 Developments in healthcare infrastructure to drive market 208
11.6.2 REST OF MIDDLE EAST & AFRICA 211
12 COMPETITIVE LANDSCAPE 214
12.1 INTRODUCTION 214
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 214
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET 215
12.3 REVENUE ANALYSIS 216
12.4 MARKET SHARE ANALYSIS 216
12.4.1 HEMATOLOGY PRODUCTS MARKET SHARE, BY KEY PLAYER, 2023 219
12.4.2 HEMOSTASIS PRODUCTS MARKET SHARE, BY KEY PLAYER, 2023 219
12.4.3 IMMUNOHEMATOLOGY PRODUCTS MARKET SHARE, BY KEY PLAYER, 2023 220
12.4.4 RANKING OF KEY MARKET PLAYERS 221
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 221
12.5.1 STARS 221
12.5.2 EMERGING LEADERS 221
12.5.3 PERVASIVE PLAYERS 222
12.5.4 PARTICIPANTS 222
12.5.5 COMPETITIVE FOOTPRINT: KEY PLAYERS, 2023 223
12.5.5.1 Company footprint 223
12.5.5.2 Product & service footprint 224
12.5.5.3 Application footprint 225
12.5.5.4 End-user footprint 226
12.5.5.5 Region footprint 227
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 228
12.6.1 PROGRESSIVE COMPANIES 228
12.6.2 RESPONSIVE COMPANIES 228
12.6.3 DYNAMIC COMPANIES 228
12.6.4 STARTING BLOCKS 228
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 230
12.7 COMPANY VALUATION & FINANCIAL METRICS 231
12.7.1 FINANCIAL METRICS 231
12.7.2 COMPANY VALUATION 231
12.8 BRAND/PRODUCT COMPARISON 232
12.9 COMPETITIVE SCENARIO 233
12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 233
12.9.2 DEALS 234
12.9.3 EXPANSIONS 235
 
13 COMPANY PROFILES 236
13.1 KEY PLAYERS 236
13.1.1 SYSMEX CORPORATION 236
13.1.1.1 Business overview 236
13.1.1.2 Products/Services offered 237
13.1.1.3 Recent developments 240
13.1.1.3.1 Product/Service launches 240
13.1.1.3.2 Expansions 240
13.1.1.4 MnM view 240
13.1.1.4.1 Key strengths 240
13.1.1.4.2 Strategic choices 240
13.1.1.4.3 Weaknesses and competitive threats 241
13.1.2 DANAHER CORPORATION 242
13.1.2.1 Business overview 242
13.1.2.2 Products/Services offered 243
13.1.2.3 MnM view 244
13.1.2.3.1 Key strengths 244
13.1.2.3.2 Strategic choices 244
13.1.2.3.3 Weaknesses and competitive threats 245
13.1.3 SIEMENS HEALTHINEERS 246
13.1.3.1 Business overview 246
13.1.3.2 Products/Services offered 247
13.1.3.3 Recent developments 249
13.1.3.3.1 Product/Service launches 249
13.1.3.3.2 Deals 249
13.1.3.4 MnM view 249
13.1.3.4.1 Key strengths 249
13.1.3.4.2 Strategic choices 250
13.1.3.4.3 Weaknesses and competitive threats 250
13.1.4 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 251
13.1.4.1 Business overview 251
13.1.4.2 Products/Services offered 252
13.1.4.3 MnM view 253
13.1.4.3.1 Key strengths 253
13.1.4.3.2 Strategic choices 253
13.1.4.3.3 Weaknesses and competitive threats 253
13.1.5 ABBOTT LABORATORIES 254
13.1.5.1 Business overview 254
13.1.5.2 Products/Services offered 255
13.1.5.3 Recent developments 256
13.1.5.3.1 Product approvals 256
 
13.1.5.4 MnM view 257
13.1.5.4.1 Key strengths 257
13.1.5.4.2 Strategic choices 257
13.1.5.4.3 Weaknesses and competitive threats 257
13.1.6 DIATRON 258
13.1.6.1 Business overview 258
13.1.6.2 Products/Services offered 258
13.1.6.3 Recent developments 259
13.1.6.3.1 Expansions 259
13.1.7 DREW SCIENTIFIC 260
13.1.7.1 Business overview 260
13.1.7.2 Products/Services offered 260
13.1.8 BIO-RAD LABORATORIES, INC. 261
13.1.8.1 Business overview 261
13.1.8.2 Products/Services offered 262
13.1.8.3 Recent developments 263
13.1.8.3.1 Product/Service launches & enhancements 263
13.1.8.3.2 Deals 264
13.1.9 HORIBA, LTD. 265
13.1.9.1 Business overview 265
13.1.9.2 Products/Services offered 266
13.1.9.3 Recent developments 268
13.1.9.3.1 Product/Service launches & approvals 268
13.1.10 NIHON KOHDEN CORPORATION 269
13.1.10.1 Business overview 269
13.1.10.2 Products/Services offered 270
13.1.10.3 Recent developments 271
13.1.10.3.1 Product/Service launches 271
13.1.10.3.2 Expansions 271
13.1.11 EKF DIAGNOSTICS HOLDINGS PLC 272
13.1.11.1 Business overview 272
13.1.11.2 Products/Services offered 273
13.1.11.3 Recent developments 274
13.1.11.3.1 Product/Service enhancements 274
13.1.11.3.2 Deals 274
13.1.12 BOULE DIAGNOSTICS AB 275
13.1.12.1 Business overview 275
13.1.12.2 Products/Services offered 276
13.1.12.3 Recent developments 277
13.1.12.3.1 PRODUCT/SERVICE LAUNCHES 277
13.1.12.3.2 Deals 278
 
13.1.13 F. HOFFMANN-LA ROCHE LTD. 279
13.1.13.1 Business overview 279
13.1.13.2 Products/Services offered 280
13.1.13.3 Recent developments 281
13.1.13.3.1 Deals 281
13.2 OTHER PLAYERS 282
13.2.1 BIOSYSTEMS: COMPANY OVERVIEW 282
13.2.2 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 283
13.2.3 DRUCKER DIAGNOSTICS: COMPANY OVERVIEW 284
13.2.4 ELITECH GROUP SAS: COMPANY OVERVIEW 285
13.2.5 ACCUREX: COMPANY OVERVIEW 286
13.2.6 STRECK: COMPANY OVERVIEW 287
13.2.7 NEOMEDICA: COMPANY OVERVIEW 288
13.2.8 CPC DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW 289
13.2.9 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW 290
13.2.10 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 291
13.2.11 PZ CORMAY S.A.: COMPANY OVERVIEW 292
13.2.12 PIXCELL MEDICAL: COMPANY OVERVIEW 293
13.2.13 RAYTO LIFE AND ANALYTICAL SCIENCES CO. LTD.: COMPANY OVERVIEW 294
13.2.14 ANALYTICON BIOTECHNOLOGIES GMBH: COMPANY OVERVIEW 295
13.2.15 TULIP DIAGNOSTICS (P) LTD.: COMPANY OVERVIEW 296
14 APPENDIX 297
14.1 DISCUSSION GUIDE 297
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 305
14.3 CUSTOMIZATION OPTIONS 307
14.4 RELATED REPORTS 307
14.5 AUTHOR DETAILS 308